skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration

Original Research

(1607) Views  (392) Full article downloads

Authors: Tryfon Rotsos, Praveen J Patel, Fred K Chen, et al

Published Date November 2010 Volume 2010:4 Pages 1271 - 1275
DOI: http://dx.doi.org/10.2147/OPTH.S14684

Tryfon Rotsos, Praveen J Patel, Fred K Chen, Adnan Tufail
Medical Retina Service, Moorfields Eye Hospital, London, UK

Purpose: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields Eye Hospital.
Methods: A retrospective analysis of case notes from the first 50 consecutive patients with Primary Care Trust funding for ranibizumab therapy for nAMD. Visual acuity outcomes and adverse events were noted, as were service delivery-related indicators.
Results: The mean (±standard deviation) age of the 50 patients was 81 ± 17 years. The mean follow-up of patients was 13.6 ± 2 (range 7.7–18) months. The mean change in visual acuity ± standard error was +4.6 ± 2.2 letters at the end of follow-up, with 26% gaining 15 letters or more. The mean (median) number of injections was 4.7 (4.5) per 12-month period. The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior to the final appraisal document from the National Institute of Health and Clinical Excellence.
Conclusions: The real-world outcomes of ranibizumab therapy in this initial cohort of patients with nAMD are comparable with those reported in the pivotal, randomized, controlled trials using fewer injections and a prn strategy of retreatment to achieve the gain in visual acuity.

Keywords: macular degeneration, retina, ranibizumab




 

Other articles by Dr Tryfon Rotsos



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
A protocol for the retina surgeon’s safe initial intravitreal injections
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Emerging treatment options in the management of non-small cell lung cancer
Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Afatinib treatment in advanced non-small cell lung cancer